A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
Recruiting in Palo Alto (17 mi)
+32 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Eli Lilly and Company
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial is testing LY3857210, a new drug, to see if it can help people with diabetic nerve pain. It aims to reduce pain by altering how nerves send pain signals.
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg LY3857210Experimental Treatment1 Intervention
Participants received 45 milligram (mg) of LY3857210 orally once daily for up to 8 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo orally once daily for up to 8 weeks.
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
CMR of Greater New HavenHamden, CT
North Georgia Clinical ResearchWoodstock, GA
Synexus Clinical Research US, Inc.Chandler, AZ
Great Lakes Research Group, Inc.Bay City, MI
More Trial Locations
Loading ...
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor